Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2021 1
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.
Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, Zehr J, Chagnon M, Roy J. Lachance S, et al. Among authors: veilleux o. Transplant Cell Ther. 2023 Jan;29(1):34.e1-34.e7. doi: 10.1016/j.jtct.2022.10.003. Epub 2022 Oct 12. Transplant Cell Ther. 2023. PMID: 36243319 Free article.
Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Kadri Y, Phan M, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J, Ahmad I. Kadri Y, et al. Among authors: veilleux o. Curr Oncol. 2022 Aug 22;29(8):5955-5962. doi: 10.3390/curroncol29080470. Curr Oncol. 2022. PMID: 36005208 Free PMC article.
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective.
Veilleux O, Claveau JS, Alaoui H, Roy J, Ahmad I, Delisle JS, Kiss T, Bambace NM, Bernard L, Cohen S, Sauvageau G, Fleury I, Mollica L, Roy DC, Serroukh Y, Lachance S. Veilleux O, et al. Transplant Cell Ther. 2022 Mar;28(3):145-151. doi: 10.1016/j.jtct.2021.12.005. Epub 2021 Dec 23. Transplant Cell Ther. 2022. PMID: 34954149 Free article.
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD.
Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, Bambace NM, Bernard L, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J. Claveau JS, et al. Among authors: veilleux o. Transplant Cell Ther. 2023 Jan;29(1):44.e1-44.e9. doi: 10.1016/j.jtct.2022.10.022. Epub 2022 Nov 2. Transplant Cell Ther. 2023. PMID: 36334654 Free article.